Joanne L Billings

Projects

Projects per year 2001 2011 2012 2013 2015 2018 2019 2021 2030

• 12 Active
• 54 Finished

Projects per year

Search results

• Women's Health in Cystic Fibrosis

  Billings, J. L.

  NIH NAT'L HEART, LUNG, AND BLOOD INSTITU

  7/5/01 → 6/30/08

  Project: Research project

  • Cystic Fibrosis 100%

• A Phase III, Open-label, Follow-on Study of Multiple Cou

  Billings, J. L.

  GILEAD SCIENCES, INC.

  8/1/05 → 7/31/08

  Project: Research project

  • Inhalation 100%
  • Patient 100%
  • Cystic Fibrosis 100%
  • Aztreonam Lysine 100%
  • Aztreonam 100%

• CF Therapeutics Development Network

  Billings, J. L.

  CYSTIC FIBROSIS FOUNDATION

  11/1/02 → 12/31/08

  Project: Research project

  • Combination Therapy 100%
  • Development 100%

• A Double-Blind, Multicenter, Multinational, Randomized,

  Billings, J. L.

  GILEAD SCIENCES, INC.

  10/1/08 → 9/30/09

  Project: Research project

  • Placebo 100%
  • Lysine 100%
  • Aztreonam 100%
  • Inhalation 100%
  • Blindness 100%

• MULTIDOSE SAFETY AND TOLERABILITY STUDY OF LIPOSOMAL AMI

  Billings, J. L.

  TRANSAVE INC

  10/25/07 → 12/31/09

  Project: Research project

  • Tolerability 100%
  • Amikacin 50%
  • Inhalation 50%

• A Phase I/II Randomized, Double-Blind, Placebo-Controlle

  Billings, J. L.

  KaloBios Pharmaceuticals, Inc.

  11/14/07 → 12/31/09

  Project: Research project

  • Placebo 100%
  • Blindness 100%
  • Pseudomonas aeruginosa 50%

• A Phase 2, Multi-Center, Randomized, Double-Blind, Place

  Billings, J. L.

  MPEX PHARMACEUTICALS, INC.

  9/1/08 → 8/31/10

  Project: Research project

  • Blindness 100%
  • Placebo-Controlled Study 50%
  • Tolerability 50%
  • Cystic Fibrosis 50%
  • Levofloxacin 50%

• Expanded Access Program for Aztreonam Lysine

  Billings, J. L.

  GILEAD SCIENCES, INC.

  1/15/08 → 12/31/10

  Project: Research project

  • Compassionate Use 100%
  • Aztreonam Lysine 100%
  • Inhalation 50%
  • Therapeutic Procedure 50%
  • Disease Exacerbation 50%

• A Phase 3, Randomized, Double-Blind, Placebo-Controlled,

  Billings, J. L.

  VERTEX PHARMACEUTICALS INCORPORATED

  9/16/09 → 9/9/12

  Project: Research project

  • Placebo 100%
  • Blindness 100%
  • Cystic Fibrosis 50%

• A PHASE 3, MULTI-CENTER, MULTINATIONAL, RANDOMIZED, DOUB

  Billings, J. L.

  MPEX PHARMACEUTICALS, INC.

  2/10/11 → 12/31/12

  Project: Research project

  • Levofloxacin 100%
  • Placebo 33%
  • Cystic Fibrosis 33%
  • Blindness 33%
  • Inhalation 33%

• A Phase 3, Open-Label, Randomized Trial To Evaluate The

  Billings, J. L.

  MPEX PHARMACEUTICALS, INC.

  3/15/12 → 3/14/13

  Project: Research project

  • Levofloxacin 100%
  • Inhalation 100%
  • Cystic Fibrosis 50%
  • Tobramycin 50%

• A Phase 3, Open-Label, Randomized Trial To Evaluate The

  Billings, J. L.

  MPEX PHARMACEUTICALS, INC.

  3/15/11 → 6/1/13

  Project: Research project

  • Inhalation 100%
  • Cystic Fibrosis 50%
  • Levofloxacin 50%
  • Tobramycin 50%

• A Phase 1b, Randomized, Double-Blind, Placebo-Controlled

  Billings, J. L.

  NIVALIS THERAPEUTICS, INC.

  1/15/13 → 1/15/15

  Project: Research project

  • Placebo 100%
  • Blindness 100%
  • Cystic Fibrosis 50%
  • Pharmacokinetics 50%

• KB001A-05, A Phase 2, Randomized, Double-blind, Placebo-

  Billings, J. L.

  KaloBios Pharmaceuticals, Inc.

  11/30/12 → 6/30/15

  Project: Research project

  • Placebo 100%
  • Blindness 100%
  • Dose 100%
  • Pseudomonas aeruginosa 100%
  • Cystic Fibrosis 50%

• 2015 Therapeutics Development Center Spring Meeting

  Billings, J. L.

  CYSTIC FIBROSIS FOUNDATION

  1/1/15 → 6/30/15

  Project: Research project

• A Phase 3, Randomized, Double Blind, Placebo Controlled,

  Billings, J. L.

  VERTEX PHARMACEUTICALS INCORPORATED

  1/31/13 → 1/31/16

  Project: Research project

  • Amaurosis 100%
  • Placebo 100%
  • Lumacaftor 100%
  • Monotherapy 50%

• Early Intervention in Cystic Fibrosis Exacerbation (eICE

  Billings, J. L.

  SEATTLE CHILDREN'S HOSPITAL, CYSTIC FIBROSIS FOUNDATION

  8/1/11 → 2/28/16

  Project: Research project

  • Cystic Fibrosis 100%

• A Phase 3 Efficacy and Safety Study of Ataluren (PTC124)

  Billings, J. L.

  PTC THERAPEUTICS, INC.

  3/20/15 → 3/20/16

  Project: Research project

  • Ataluren 100%
  • Cystic Fibrosis 25%

• Prospective Observational Study to Evaluate Biomarkers

  Billings, J. L. & Dunitz, J. M.

  FOUNDATION FOR THE NAT'L INST. OF HEALTH

  4/1/12 → 6/30/16

  Project: Research project

  • Kidney 100%
  • Safety 100%
  • Evaluation 100%
  • Qualifications 100%
  • Biological Marker 100%

• VX12-809-105: A Phase 3, Rollover Study to Evaluate

  Billings, J. L.

  VERTEX PHARMACEUTICALS INCORPORATED

  12/6/13 → 12/6/16

  Project: Research project

  • Ivacaftor 100%
  • Cystic Fibrosis 100%
  • Lumacaftor 100%

• N91115-2CF-05 (SNO-6): A Phase 2, Randomized, Double-Bli

  Billings, J. L.

  NIVALIS THERAPEUTICS, INC.

  9/15/15 → 12/31/16

  Project: Research project

  • Cystic Fibrosis 100%
  • Placebo 33%
  • Patient with Cystic Fibrosis 33%
  • Inpatient 33%
  • Blindness 33%

• A Phase 1b, Randomized, Double-Blind, Placebo-Controlled

  Billings, J. L.

  NIVALIS THERAPEUTICS, INC.

  1/31/15 → 1/31/17

  Project: Research project

  • Placebo 100%
  • Blindness 100%
  • Cystic Fibrosis 50%
  • Pharmacokinetics 50%
  • Cavosonstat 50%

• A Prospective, 5-year Registry Study to Monitor

  Billings, J. L.

  GILEAD SCIENCES, INC.

  7/1/11 → 7/1/17

  Project: Research project

  • Pseudomonas aeruginosa 100%
  • Aztreonam 100%
  • Cystic Fibrosis 100%
  • Patient with Cystic Fibrosis 100%

• DMP-CF-303: Long Term Administration of Inhaled Mannitol

  Billings, J. L.

  PHARMAXIS LTD

  10/1/14 → 10/1/17

  Project: Research project

  • Cystic Fibrosis 100%
  • Mannitol 100%

• Multicenter Clinical Phenotyping of Cystic Fibrosis

  Billings, J. L.

  UNIVERSITY OF CALIFORNIA SAN DIEGO, GILEAD SCIENCES, INC.

  12/1/15 → 11/13/17

  Project: Research project

  • Cystic Fibrosis 100%
  • Phenotype 100%

• VX15-371-101: A Phase 2a, Randomized, Double-blind

  Billings, J. L.

  VERTEX PHARMACEUTICALS INCORPORATED

  12/15/15 → 5/31/18

  Project: Research project

  • Placebo 100%
  • Cystic Fibrosis 100%
  • Crossover Study 100%
  • Blindness 100%

• A Phase 2, Multi-Center, Randomized, Placebo-Controlled

  Billings, J. L.

  SEATTLE CHILDREN'S HOSPITAL, NIH NAT'L HEART, LUNG, AND BLOOD INSTITU

  9/1/13 → 6/30/18

  Project: Research project

  • Placebo-Controlled Study 100%
  • Placebo 100%
  • Cystic Fibrosis 100%
  • Gallium Nitrate 100%

• VX14-661-110: A Phase 3, Open-label, Rollover Study to E

  Billings, J. L. & Laguna, T.

  VERTEX PHARMACEUTICALS INCORPORATED

  10/5/15 → 10/5/18

  Project: Research project

  • Ivacaftor 100%

• A Two-Part Multicenter Prospective Longitudinal Study

  Billings, J. L.

  SEATTLE CHILDREN'S HOSPITAL, CYSTIC FIBROSIS FOUNDATION

  7/1/14 → 1/31/19

  Project: Research project

  • Longitudinal Study 100%

• VX16-809-120: A Post-approval Observational Study to Evaluate the Long-term Effectiveness and Safety ofOrkambi in US Patients Who Completed Study VX12-809-105 Part A

  Billings, J. L.

  VERTEX PHARMACEUTICALS INCORPORATED

  4/1/18 → 12/31/19

  Project: Research project

  • Observational Study 100%
  • Patient 100%

• PTI-428-06: A Phase 2, Multicenter, Randomized, Double-Blind,Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect of PTI-428 inSubjects with Cystic Fibrosis

  Billings, J. L.

  PROTEOSTASIS THERAPEUTICS, INC.

  9/28/18 → 1/1/20

  Project: Research project

  • Placebo-Controlled Study 100%
  • Tolerability 100%
  • Cystic Fibrosis 100%
  • Blindness 100%
  • Pharmacokinetics 100%

• VX15-440-101: A Phase 2, Randomized, Double-blind, Contr

  Billings, J. L.

  VERTEX PHARMACEUTICALS INCORPORATED

  11/6/16 → 1/1/20

  Project: Research project

  • Blindness 100%
  • Cystic Fibrosis 100%
  • Combination Therapy 50%

• Novartis CQBW276X2201: A randomized, double blind, place

  Billings, J. L.

  NOVARTIS PHARMACEUTICALS CORPORATION

  6/1/17 → 1/11/20

  Project: Research project

  • Blindness 100%
  • Placebo-Controlled Study 50%
  • Tolerability 50%
  • Cystic Fibrosis 50%
  • Pharmacodynamics 50%

• VX17-659-102: A Phase 3, Randomized, Double-blind, Contr

  Billings, J. L.

  VERTEX PHARMACEUTICALS INCORPORATED

  4/12/18 → 3/12/20

  Project: Research project

  • Blindness 100%
  • Mutation 100%
  • Combination Therapy 50%
  • Cystic Fibrosis 50%
  • Safety 50%

• Sexual and Reproductive Health in Adult Women with Cystic Fibrosis

  Billings, J. L.

  UNIVERSITY OF PITTSBURGH, CYSTIC FIBROSIS FOUNDATION

  4/1/19 → 3/31/20

  Project: Research project

  • Reproductive Public Health 100%
  • Woman 100%
  • Cystic Fibrosis 100%
  • Adult 100%

• The EPIC Observational Study: Longitudinal Assessment of

  Billings, J. L.

  SEATTLE CHILDREN'S HOSPITAL, CYSTIC FIBROSIS FOUNDATION

  9/1/13 → 10/1/20

  Project: Research project

  • Assessment 100%
  • Observational Study 100%
  • Child 50%
  • Pseudomonas aeruginosa 50%
  • Therapeutic Procedure 50%

• GS-US-404-1808: A Phase 2b, Dose-Ranging Study of the Ef

  Billings, J. L.

  GILEAD SCIENCES, INC.

  11/1/16 → 11/1/20

  Project: Research project

  • Dose 100%
  • Cystic Fibrosis 100%
  • Adult 50%

• G551D Observational Study

  Billings, J. L.

  SEATTLE CHILDREN'S HOSPITAL, CYSTIC FIBROSIS FOUNDATION

  9/1/11 → 12/31/20

  Project: Research project

  • Observational Study 100%

• A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safetyof 445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508delMutation and a Gating or Residual Function Mutation (F/G and F/RF Ge

  Billings, J. L.

  VERTEX PHARMACEUTICALS INCORPORATED

  5/23/19 → 1/1/21

  Project: Research project

  • Combination Therapy 100%
  • Cystic Fibrosis 100%
  • Blindness 100%

• PTI-808-01: A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PTI-808 inHealthy Adult Subjects and in Adults with Cystic Fibrosis

  Billings, J. L.

  PROTEOSTASIS THERAPEUTICS, INC.

  7/1/18 → 1/1/21

  Project: Research project

  • Tolerability 100%
  • Cystic Fibrosis 100%
  • Pharmacokinetics 100%
  • Normal Human 50%

• A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacyof VX-121 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis

  Billings, J. L.

  VERTEX PHARMACEUTICALS INCORPORATED

  3/21/19 → 1/1/21

  Project: Research project

  • Combination Therapy 100%
  • Cystic Fibrosis 100%
  • Blindness 100%
  • Controlled Study 100%

• VX17-659-105: A Phase 3, Open-label Study Evaluating the

  Billings, J. L.

  VERTEX PHARMACEUTICALS INCORPORATED

  5/9/18 → 5/1/21

  Project: Research project

  • Combination Therapy 100%
  • Cystic Fibrosis 100%

• APPLAUD: A double-blinded, randomized, placebo-controlled, Phase 2 study of the efficacy and safety ofLAU-7B in the treatment of cystic fibrosis through correction of the AA/DHA imbalance

  Billings, J. L.

  LAURENT PHARMACEUTICALS INC

  11/1/18 → 10/31/21

  Project: Research project

  • Placebo 100%
  • Cystic Fibrosis 100%

• University of Minnesota Additional Research Coordinator

  Billings, J. L.

  CYSTIC FIBROSIS FOUNDATION

  1/1/15 → 3/31/22

  Project: Research project

  • Research 100%
  • University 100%
  • Minnesota 100%

• A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VX-561 in Subjects aged 18 Years and Olderwith Cystic Fibrosis

  Billings, J. L.

  VERTEX PHARMACEUTICALS INCORPORATED

  6/1/19 → 7/31/22

  Project: Research project

  • Cystic Fibrosis 100%

• A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis

  Billings, J. L.

  VERTEX PHARMACEUTICALS INCORPORATED

  7/30/19 → 12/31/22

  Project: Research project

  • Combination Therapy 100%
  • Cystic Fibrosis 100%

• A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

  Billings, J. L.

  VERTEX PHARMACEUTICALS INCORPORATED

  7/30/19 → 12/31/22

  Project: Research project

  • Combination Therapy 100%
  • Cystic Fibrosis 100%

• Collaborative Cohort of Cohorts for COVID-19 Research (C4R)

  Billings, J. L.

  NATIONAL JEWISH HEALTH, NIH NAT'L HEART, LUNG, AND BLOOD INSTITU

  3/3/21 → 12/31/22

  Project: Research project

• SIMPLIFY-IP-19: A protocol to test the impact of discontinuing chronic therapies in people with cystic fibrosis on highly effective CFTR modulator therapy (SIMPLIFY)

  Billings, J. L.

  SEATTLE CHILDREN'S HOSPITAL, CYSTIC FIBROSIS FOUNDATION

  1/1/20 → 12/31/22

  Project: Research project

  • Cystic Fibrosis 100%

• Translational Therapeutics Development Center

  Billings, J. L. & Regelmann, W. E.

  CYSTIC FIBROSIS FOUNDATION

  1/1/09 → 3/31/23

  Project: Research project